Project: Targeting SUMOylation to treat resistant diffuse large B-cell Lymphoma
| Acronym | SUBLYME (Reference Number: 10918) |
| Duration | 01/03/2017 |
| Project Topic | The SUBLYME consortium will develop a novel first-in-class drug for treatment of Diffuse Large B-cell Lymphoma (DLBCL), one of the most common blood/lymphatic cancers. This drug will inhibit a specific molecular process (SUMOylation) that is selectively required for survival of treatment-resistant tumours, including DLBCL. The project will perform necessary preclinical development to generate the data package that is required for subsequent regulatory pre- and clinical validation. |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 6 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | UbiQ Bio BV | Coordinator | Netherlands |
| 2 | Biovica International AB | Partner | Sweden |
| 3 | ElexoPharm GmbH | Partner | Germany |
| 4 | Porsolt SAS | Partner | France |
| 5 | Klinikum rechts der Isar der Technischen Universität München | Partner | Germany |